Slide 1: H1 2021 Results
H1 2021 Results Matthias Gaertner CEO/CFO August 12, 2021
Slide 2: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 2
Slide 3: Highlights: Ongoing & sustainable growth story
Executive summary Highlights: Ongoing & sustainable growth story Ongoing progress in strategy implementation • Synergy potentials & cross-selling opportunities: From 330 to > 530 specialized partner pharmacies • Ongoing screening of M&A targets mainly with focus on compounding and digitalization Pha
Slide 4: Ongoing success story after Q2 2020 effected by Corona effects
Executive summary Ongoing success story after Q2 2020 effected by Corona effects Revenue €m EBITDA pre¹ €m EBT pre¹ €m 9.5 316 319 8.8 8.6 7.1 4.8 163 160 174 4.3 4.0 130 3.8 3.7 3.1 3.0 2.7 2.2 margin margin 2.5 2.7 2.3 1.2 2.3 2.2 2.3 2.0 1.9 1.6 0.9 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q4
Slide 5: H1 2021 – Growth story reflected in the sustainable increase of key figures
Executive summary H1 2021 – Growth story reflected in the sustainable increase of key figures Revenue €m EBITDA pre¹ €m EBT pre¹ €m 18.2 635 15.7 293 6.5 4.9 H1 2020 H1 2021 H1 2020 H1 2021 H1 2020 H1 2021 ¹ EBITDA and EBT without extraordinary expenses: adjusted for extraordinary expenses for stock
Slide 6: H1 2021 – Split by segments
Executive summary H1 2021 – Split by segments Revenue by segment1 EBITDA pre by segment2 5% 20% 95% 80% Pharmaceutical Supply Pharmaceutical Supply Patient-specific Therapies Patient-specific Therapies ¹ External revenue excl. Services segment (€0.3m); 2 EBITDA without extraordinary expenses: adjust
Slide 7: ESG strategy well under way
Sustainability ESG strategy well under way Code of conduct published end of 2020 • Finalize and further establish ESG strategy For the first time publication of a “voluntary with focus on: report 2020” based on CSR-RUG¹ • Environmental concerns Implementation of ESG targets in the remuneration • Emp
Slide 8: Management structure
Introduction Management structure Executive Board Supervisory Board Chairman & CFO COO CINO1 Chairman Deputy Member Member Matthias Gärtner Mi-Young Miehler Christoph Prußeit Dr. Yann Samson Chairman Klaus J. Buß Dr. Anke Nestler Joachim Messner Audit Remuneration & Committee Nomination Committee Ch
Slide 9: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 9
Slide 10: H1 2021 – Financials
Financial overview H1 2021 – Financials In € million H1 2021 H1 2020 ∆% Revenue 634.9 292.9 116.8 • Strong revenue growth driven by organic & COGS¹ 275.4 inorganic growth 603.0 118.9 ratio in % of revenue 95.0% 94.0% • Higher personnel expenditures mainly due to current and expected strong growth Pe
Slide 11: H1 2021 – Revenue-bridge per segment
Financial overview H1 2021 – Revenue-bridge per segment H1 YoY Revenue in €m H1 2020 Organic Inorganic H1 2021 Pharmaceutical Supply 262.1 63.3 278.2 603.6 • Inorganic growth strongly supported thereof Cranach Pharma 0 0 278.2 278.2 by synergy effects Patient-specific Therapies 30.6 -1.0 1.4 31.0 •
Slide 12: Q2 2021 – Record quarter driven by strong inorganic and organic growth
Financial overview Q2 2021 – Record quarter driven by strong inorganic and organic growth Q2 YoY Revenue in €m Q2 2020 Organic Inorganic Q2 2021 Pharmaceutical Supply 113.9 51.5 138.6 303.9 • Compared to a very weak Corona- thereof Cranach Pharma 0 0 138.6 138.6 loaded Q2 2020 Patient-specific Thera
Slide 13: H1 2021 – Substantial improvement of earnings margins
Financial overview H1 2021 – Substantial improvement of earnings margins Pharmaceutical Patient-specific Internal Services and Group Supply Therapies IFRS consolidation In € million H1 2021 H1 2020 H1 2021 H1 2020 H1 2021 H1 2020 H1 2021 H1 2020 Revenue (external) 603.6 262.1 31.0 30.6 0.3 0.2 634.9
Slide 14: Financing power - Strong financial position to invest in future growth
Financial overview Financing power- Strong financial position to invest in future growth As of June 30, 2021 In € million Organic growth Syndicated loan 45.9 • Up to €10m to be invested in new labs in Thereof called -28.4 Berlin; of which €5m have already been spent Cash & cash equivalents 75.1 Exte
Slide 15: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 15
Slide 16: Revenue Forecast slightly raised – Earnings forecast unchanged
Guidance 2021 Revenue Forecast slightly raised – Earnings forecast unchanged New Old In € million 2020 Growth % 2021F¹ 2021F¹ Group revenue 1,200 –1,300 1,150 –1,200 626.0 92 – 107 + External growth will be substantially driven by the acquisitions of Cranach Pharma, and EBITDA pre² 38 – 39 38 – 39 1
Slide 17: Good plan for organic growth and M&A
Growth strategy Good plan for organic growth and M&A • Establish new labs in Berlin by the end of 2021– to • Ongoing M&A focusing on be able to triple manufacturing capacities • Compounding - increase in capacities for • Expand “blistering” focusing on high-priced drugs enhanced production of indivi
Slide 18: Appendix
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 18
Slide 19: Key figures (1/2)
Appendix Key figures (1/2) in € thousand H1 2021 H1 2020 ∆ in % Q2 2021 Q2 2020 ∆ in % Revenue 634,927 292,884 116.8% 319,019 130,050 145.3% Pharmaceutical Supply 603,560 262,074 130.3% 303,932 113,857 166.9% Patient-Specific Therapies 31,047 30,604 1.4% 14,912 16,063 -7.2% Services 320 206 55.3% 17
Slide 20: Key figures (2/2)
Appendix Key figures (2/2) in € thousand H1 2021 H1 2020 ∆ in % Q2 2021 Q2 2020 ∆ in % Earnings per share (in €) Undiluted 0.32 0.21 52.4% 0.17 0.06 183.3% Diluted 0.31 0.21 47.6% 0.17 0.05 240.0% Investments (CAPEX) 5,760 2,215 160.0% 3,131 1,274 145.8% Cash flow from operating activities 29,654 6,
Slide 21: Consolidated statement of comprehensive income
Appendix Consolidated statement of comprehensive income in thousand € H1 2021 H1 2020 ∆ in % Q2 2021 Q2 2020 ∆ in % Revenue 634,927 292,884 116.8% 319,019 130,050 145.3% Change in stocks of finished goods & work-in progress 31 13 138.5% -53 -17 211.8% Work performed and capitalized 269 17 > 1,000% 2
Slide 22: Consolidated balance sheets
Appendix Consolidated balance sheets June 30, June 30, Assets in thousand € FY 2020 ∆ in % Liabilities in thousand € FY 2020 ∆ in % 2021 2021 Non-current assets 227,558 58,232 290.8% Equity Intangible assets 200,659 35,237 469.5% Subscribed capital 20,265 16,085 26.0% Property, plant and equipment 9
Slide 23: Consolidated cash flow statement H1 2021 (1/2)
Appendix Consolidated cash flow statement H1 2021 (1/2) in thousand € H1 2021 H1 2020 ∆ in % Q2 2021 Q2 2020 ∆ in % Cash flow from operating activities Net income for the period 6,273 3,169 97.9% 3,432 859 299.5% Depreciation and amortization on non-current assets 7,673 1,622 373.1% 3,838 995 285.7%
Slide 24: Consolidated cash flow statement H1 2021 (2/2)
Appendix Consolidated cash flow statement H1 2021 (2/2) in thousand € H1 2021 H1 2020 ∆ in % Q2 2021 Q2 2020 ∆ in % Cash flow from investment activities Payments made for investments in intangible assets -1,003 -671 49.55% -563 -435 29.4% Payments from disposals of intangible assets 250 0 0 0 Paymen
Slide 25: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations Phone +49 30 232 566 800 ir@medios.ag 25
Slide 26: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 27: H1 2021 Results
H1 2021 Results Matthias Gaertner CEO/CFO August 12, 2021